Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spiolto Respimat effects on cardiac function in hyperinflated COPD
NCT04231214Phase 4Completed
- Sponsor
- Fraunhofer ITEM
- Start
- Jan 2020
- Primary completion
- Apr 2023
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tiotropium + olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Fraunhofer ITEM. Primary endpoint: Left Ventricular End-Diastolic Volume Index at Day 24. Started Jan 2020; status: completed.
02
Drugs
tiotropium + olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04231214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231214.